ADVERTISEMENT
Not Just Bulk Drugs, This Segment Too Is Doing Well For Divi’s Laboratories
Besides API, this segment has been working in favour of Divi’s Laboratories.
07 Sep 2020, 06:25 PM IST
Indian pharmaceutical companies saw their businesses grow in the pandemic-marred first quarter, mostly aided by bulk drugs amid global supply chain disruptions and trade pushback against China. But there’s another segment that has been working in favour of Divi’s Laboratories Ltd.: custom synthesis.Founded 29 years ago by Murali Divi, the company’s product portfolio comprises generic active pharmaceutical ingredients business, or raw...
I’m already a Subscriber Sign In
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Full Access to
NDTV Profit App
Exclusives
Premium Stories
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Minimal Ad
Experience
Members-Only
Rewards
Still Not convinced ? Know More
Get live Stock market updates, Business news, Today’s latest news, Trending stories, and Videos on NDTV Profit.
ADVERTISEMENT